Community Pharmacists’ Measurement of Health-related Quality of Life in Outpatients Taking High-risk Drugs

Ichimura, Takenori; Ogawa, Chiaki; H, Murata; Miyahara, Katsuaki; Satoshi, Yuge; Tsukioka, Ryota; Kado, Keisuke; Yoshimura, Tomonobu; Suzuki, Koichi; Nomura, Hisanaga; Shimizu, Hiroki

doi:10.21203/rs.3.rs-858889/v1

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 We thus aimed to conduct a prospective observational study between October 2020 and March 2022 at 29 community pharmacies and 71 pharmacists in 12 regions and cities in Japan. 13 In particular, the health-related QOL and QALY of patients undergoing hormonal therapy for breast cancer were assessed.…”

Section: Introductionmentioning

confidence: 99%

Community pharmacists’ measurement of health-related quality of life for breast cancer with positive hormone receptors: A prospective observational study

2023

Self Cite

View full text Add to dashboard Cite

Objectives: Many patients with hormone-receptor positive breast cancer undergo prolonged treatment. However, the long-term patient quality of life assessment has not been examined. Using community pharmacists’ assistance is one method for assessing long-term quality of life. Thus, this study aimed to understand the ongoing health-related quality of life and quality-adjusted life year among breast cancer patients so that community pharmacists may contribute to their pharmacotherapy. Methods: We conducted a prospective observational study with 22 breast cancer patients who had health-related quality of life at the initial measurement and 6 months later. Results: Regarding the health-related quality of life, quality-adjusted life year concerning all patients was 0.890 (95% confidence interval: 0.846–0.935). Quality-adjusted life year concerning those younger than 65 years was 0.907 (95% confidence interval: 0.841–0.973), and that for individuals older than 65 years was 0.874 (95% confidence interval: 0.804–0.943). The adjuvant chemotherapy group had a lower health-related quality of life at the initial measurement (0.887; 95% confidence interval: 0.833–0.941) but showed a higher quality of life 6 months later (0.951; 95% confidence interval: 0894–1.010). Quality-adjusted life year for individuals regarding adjuvant chemotherapy was 0.919 (95% confidence interval: 0.874–0.964). In contrast, the life-prolonged group had a higher health-related quality of life at the initial measurement, which was lower 6 months later. Conclusions: As a result of measuring quality of life using the EuroQol 5-dimensions-5-levels, this study revealed a decline in health-related quality of life in patients undergoing hormonal therapy for breast cancer. The study is expected to assist community pharmacists in managing outpatients.

show abstract

Section: Introductionmentioning

confidence: 99%